Nexalin Technology, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Nexalin Technology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $10 per $100 of sales comes from others' credit, against $38 from others' credit three years earlier. Less money tied up than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-33.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 66% of Healthcare companies in United States.
Cash Locked Ratio
−$10Money owed to suppliers is larger than money owed by customers plus stock: $10 per $100 of sales comes from others' credit, against $38 from others' credit three years earlier.
Less money tied up than 95% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 77%
Sales fell 77% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-77% / -38%In 3 years sales changed by -77% while total assets changed by -38%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
93%Of every $100 the company owns, $93 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 66% of Healthcare companies in United States.
Tangible Net Worth Ratio
91%Of every $100 of net worth, $91 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 73% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Nexalin Technology, Inc. made a loss over the last year. Nexalin Technology, Inc. owes $0.49 for every $1 it owns. Nexalin Technology, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossNexalin Technology, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.40The share price is 1.40 times Nexalin Technology, Inc.'s book value per share, lower than 70% of Healthcare companies in United States.
Market cap
$2 MThe total market value of all of Nexalin Technology, Inc.'s shares at today's price (share price × number of shares), smaller than 98% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$2 MWhat Nexalin Technology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.45Net worth divided by the number of shares. The share price of $2.03 is 1.4 times this, which is the P/B above.
Return on equity (ROE)
-240.2%Nexalin Technology, Inc. lost 240.2% of its shareholders' money over the last year, lower than 87% of Healthcare companies in United States.
Owes vs Owns
0.49×Nexalin Technology, Inc. owes $0.49 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Dividend yield
NoneNexalin Technology, Inc. does not currently pay a dividend.
Revenue growth
+79%Revenue rose 79% in the year to Dec 2025, and shrank 39% a year on average over 3 years.
Profit growth
LossNexalin Technology, Inc. made a loss in each of the last two years.
Profit margin
-2725.8%Nexalin Technology, Inc. lost $2726 for every $100 of revenue.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Nexalin Technology, Inc.: $2 M ÷ $2 M (30 Jun 2026) = 1.4.
What is Nexalin Technology, Inc.'s return on equity?
Nexalin Technology, Inc. lost 240.2% of its shareholders' money over the last year, lower than 87% of Healthcare companies in United States.
How much does Nexalin Technology, Inc. owe compared with what it owns?
Nexalin Technology, Inc. owes $0.49 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Does Nexalin Technology, Inc. pay a dividend?
No. Nexalin Technology, Inc. does not currently pay a dividend.
Is Nexalin Technology, Inc.'s revenue growing?
Revenue rose 79% in the year to Dec 2025, and shrank 39% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.